of DON3G. However, the absorbed fraction of DON3G, recovered as DON, was approximately 5 times lower than after PO DON administration, 16.1 ± 5.4 compared with 81.3 ± 17.4 %. Analysis of phase II metabolites revealed that biotransformation of DON and DON3G in pigs mainly consists of glucuronidation, whereas in chickens predominantly conjugation with sulphate occurred. The extent of phase II metabolism is notably higher for chickens than for pigs, which might explain the differences in sensitivity of these species to DON. Although in vitro studies demonstrate a decreased toxicity of DON3G compared with DON, the species-dependent toxicokinetic data and in vivo hydrolysis to DON illustrate the toxicological relevance and consequently the need for further research to establish a tolerable daily intake.
Introduction
Mycotoxin contamination of food and feed has been classified by several authors as the most important chronic dietary risk for human and animal health. The Fusarium mycotoxin deoxynivalenol (DON) is one of the most frequently occurring mycotoxins, contaminating 56 % of feed and feed raw materials worldwide (Schatzmayr and Streit 2013) . Additionally, feed can be contaminated with modified forms of DON, such as deoxynivalenol-3-β-dglucoside (DON3G), causing a possible underestimation of the degree of contamination.
Following a request from the European Commission, the risks to human and animal health related to modified forms of the Fusarium mycotoxins zearalenone, nivalenol, T-2 and HT-2 toxin and fumonisins were evaluated by the European Food Safety Authority Panel on Contaminants in the Food Chain (EFSA CONTAM Panel). The panel considered it appropriate to assess human exposure to modified forms of the various toxins in addition to the parent compounds, because modified forms may be hydrolysed into the parent compounds or released from the matrix during digestion. However, no risk assessment for modified forms of DON is currently available (EFSA CONTAM Panel 2014) . Concerning acetylated forms of DON, 3-acetyldeoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON), both ADONs were completely absorbed and presystemically hydrolysed to DON in pigs (Broekaert et al. 2015b ). In chickens, for both ADONs a higher absorbed fraction was observed compared with DON, as well as a presystemic hydrolysis of 3ADON and 15ADON to DON of 100 and 75.4 %, respectively (Broekaert et al. 2015b) .
Recent occurrence data (2010) (2011) (2012) (2013) (2014) for DON and DON3G have been reviewed for unprocessed cereals, such as wheat, maize, barley, oat, rye and spelt (Broekaert et al. 2015a) . Observed incidence, average concentration and maximum detected concentration for DON and DON3G were 84, 458, 27, 088 , and 55 %, 85 µg/kg, 170 µg/kg, respectively. DON3G concentrations exceeding those of free DON have been detected in some hard red spring wheat samples (Sasanya et al. 2008) , which indicate its high prevalence.
The susceptibility of animal species to DON can be ranked in the following decreasing order: pigs > mice > rats > poultry ≈ ruminants (Pinton and Oswald 2014) . The toxicity of DON depends on its ability to efficiently cross biological barriers in humans and animals, such as the intestinal and the blood-brain barrier. At the cellular level, DON primarily inhibits protein synthesis. Consequently, fast dividing cells such as intestinal epithelial and immune cells will be more susceptible to the detrimental effects of DON (Maresca 2013; Pestka 2010; Rotter et al. 1996) . The cellular toxicity is mainly attributed to the presence of the epoxide moiety (Pestka 2010; Ueno et al. 1973 ). This functional group allows DON, and trichothecenes in general, to bind to ribosomes and inhibit peptide bond formation. Additionally, DON in lower doses causes a 'ribotoxic stress response', leading to proinflammatory responses (Pestka 2008) . Presumably glucosylation of DON greatly reduces its toxicity. The phytotoxicity of DON and DON3G was studied by means of a wheat germ extract-coupled in vitro transcription/translation system. While 1 µM of DON significantly decreased translation by 63 %, 5 and 20 µM of DON3G resulted in a translation decrease of only 3.1 and 8.0 %, respectively (Poppenberger et al. 2003) . In a growth test with algal cells, 80 µM of DON3G, unlike an equimolar amount of DON, did not significantly alter growth (Suzuki and Iwahashi 2015) . Decreased toxicity has also been observed in mice, where DON3G was largely incapable of evoking cytokine or chemokine responses in the spleen of mice orally gavaged with 2.5 mg/kg body weight (bw), in contrast to DON, except for slight elevations in IL-1β mRNA expression . Recently, in silico analysis suggested that DON3G, unlike DON, was unable to bind to the ribosome peptidyl transferase centre (Pierron et al. 2015) . Additionally, comparative cytotoxicity of DON and DON3G was assessed on both proliferative Caco-2 cells by means of quantitation of the ATP present. After 48-h exposure to DON, an IC 50 of 1.3 µM (0.384 µg/mL) was observed in proliferative Caco-2 cells. In contrast, no cytotoxicity was observed with up to 10 µM of DON3G (Pierron et al. 2015) .
Regarding the hydrolysis of DON3G to DON, different in vitro studies reported that DON3G was not hydrolysed to DON in the human upper gastrointestinal (GI) tract by means of acid, stomach and gut juice, or recombinant human cytosolic β-glucosidase (Berthiller et al. 2011; Dall'Erta et al. 2013; De Angelis et al. 2014; De Nijs et al. 2012) . Regarding the human lower GI tract, some in vitro experiments indicate that hydrolysis can take place and that the intestinal microbiota composition and their abundance can play an important role (Abbott 2004; Berthiller et al. 2011; Dall'Erta et al. 2013; Gratz et al. 2013; Hattori and Taylor 2009) . In vitro models do not take into account important physiological and anatomical factors within and between different animal species and humans, such as intestinal mucosa and luminal content composition (enzymes, microbiota), blood flow in internal organs and enterohepatic recirculation (Gonzalez-Arias et al. 2013) . To estimate these factors and especially the interactions between them, species-specific in vivo trials remain mandatory. Versilovskis et al. (2012) reported a first DON3G in vivo study in which two rats were fed 25 µg of DON3G by oral gavage, followed by blood collection at 17 and 1 3 55 min post-administration. DON was detected in the stomach albeit at only 2 % of the applied dose. This confirms the conclusions of the in vitro studies; that is hydrolysis of DON3G in the stomach is negligible. Further down in the GI tract, DON3G could only be detected at 2-3 % of the applied dose in the small intestine and at 1-2 % in the colon. This remarkable decrease in DON3G in the small intestine is probably due to the presence of intestinal β-glucosidases (Versilovskis et al. 2012) . Nagl et al. (2012) orally administered DON and an equimolar dose of DON3G to six rats, followed by urine and faeces collection over a period of 2 days. After PO administration of DON3G, less than 4 % of the administered dose was recovered in urine, of which 35 % as DON, 33 % as DON-glucuronide (DON-GlcA), 24 % as de-epoxy-deoxynivalenol (DOM-1) and 8 % as DON3G. The presence of urinary DON clearly demonstrates the hydrolysis upon ingestion. In comparison, after PO DON administration, 15 % of the dose was recovered in urine as DON-GlcA, DON and DOM-1, indicating a relatively low oral bioavailability for DON3G compared with DON in rats. Analysis of faecal samples of rats dosed with DON3G revealed that the vast majority of the metabolites of DON3G were excreted as DON and DOM-1 (sum: 99.5 ± 0.4 %). Only traces of DON3G were detected, indicating that intestinal microbiota are effective in hydrolysing this masked mycotoxin in rats (Nagl et al. 2012) . Recently, the results in rat were supported by in vivo experiments performed in pig by the same research group (Nagl et al. 2014) . After intravenous (IV) administration of DON3G, no DON was detected in plasma, indicating that systemic hydrolysis of DON3G is negligible. After oral administration of DON3G, 40.3 % of the dose was recovered in urine of which 2.6 % as DON3G, next to DON (21.6 %), DON-15-glucuronide (DON15GlcA) (6.8 %), DOM-1 (5.9 %) and DON-3-glucuronide (DON3GlcA) (3.4 %) (Nagl et al. 2014) . Consequently, it was concluded that in vivo cleavage of DON3G predominantly occurs in the (lower) digestive tract. Oral bioavailability was lower for DON3G than for DON, deduced from the recovered DON equivalent amounts in urine, namely 84.8 for DON and 40.3 % for DON3G (Nagl et al. 2014) . Moreover, the oral bioavailability for both compounds in pig was remarkably higher than in rat.
However, both study designs in rat and pig do not allow determination of the site of hydrolysis (GI microbiota, GI tissues, portal blood, liver, systemic blood). Sampling portal blood would offer a huge advantage as it would allow to differentiate between presystemic and systemic hydrolyses and therefore significantly contribute to the understanding of the (pre)systemic hydrolysis of DON3G. Trans-splenic portal vein catheterisation in pigs has previously been described ) and was used to study the presystemic metabolisation of xenobiotics ).
Therefore, portal vein catheterisation offers a valuable tool to study possible presystemic hydrolysis of DON3G in pigs.
Currently, literature reports regarding the toxicokinetics of DON3G in humans and other animal species, such as broiler chickens, are scarce. Warth et al. performed a study with a human volunteer consuming a diet naturally contaminated with 138 µg DON/day, 7 μg DON3G/day and 20 µg 3ADON/day. DON3G, in contrast to DON, could not be detected in urine (Warth et al. 2013) . For broiler chickens, no data are available, although poultry have a high exposure to DON3G given their mainly cereal-based diet. The GI anatomy, physiology and distinct microbiota species composition and abundance of poultry further contribute to the relevance of performing research in these species.
The goal of this study was to determine the absolute oral bioavailability, the degree of hydrolysis and the main toxicokinetic parameters of DON3G in broiler chickens and pigs. Additionally, portal vein catheterisation in pigs allowed determination of the site of presystemic hydrolysis.
Materials and methods

Standards, reagents and solutions
DON (>99 % purity) was obtained from Fermentek (Jerusalem, Israel). DON3G was enzymatically synthesised, purified and verified using nuclear magnetic resonance (NMR) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Michlmayr et al. 2015) . No remaining DON (<0.05 %) was detected in the produced DON3G. DON and DON3G were dissolved in analytical-grade ethanol (EtOH) (Merck, Brussels, Belgium), yielding a stock solution of 10 mg/mL, and were used for animal trials and analytical experiments. DOM-1 (50 µg/mL) and 13 C 15 -DON (stable isotopically labelled internal standard, IS, 50 µg/ mL) stock solutions in acetonitrile were purchased from Sigma-Aldrich (Diegem, Belgium). All stock solutions were stored at ≤−15 °C. Individual working standard solutions of 10 µg/mL, used for the analytical experiments, were prepared by diluting the above stock solutions with UHPLC-MS grade acetonitrile (Biosolve, Valkenswaard, The Netherlands). All working standard solutions were stored at ≤−15 °C. Standard mixture working solutions containing DON, DON3G and DOM-1 of 1 and 0.1 µg/ mL were prepared by mixing appropriate dilutions of the individual working standard solutions in UHPLC-MS acetonitrile, stored at 2-8 °C. Solutions of DON in acetonitrile have been reported to be stable for 24 months at room temperature (Widestrand and Pettersson 2001) . Water, methanol and glacial acetic acid were of UHPLC-MS grade (Biosolve). Microfilters (GV-PVDF 0.22 µm) were obtained from Millipore (Overijse, Belgium).
Animal trials
Broiler chickens
Six broiler chickens (Ross 308) were purchased from the Institute for Agriculture and Fisheries Research (Melle, Belgium) at the age of 3 weeks, as hatched. Water and feed were given ad libitum. The pen was climate-controlled with temperatures between 21 and 25 °C, a relative humidity between 40 and 60 % and an applied light schedule similar to commercial installations (18-h light/6-h dark). After a 1-week acclimatisation period, the animals had an average bw ± standard deviation (SD) of 1400 ± 131 g, and three broiler chickens were treated with DON3G by IV bolus injection in the vena basilica, and three broiler chickens received DON3G PO by means of gavage in the crop. After a washout period of 1 day, a crossover design was applied, which resulted in a PO and IV administration of DON3G in each of the six broiler chickens. Next, a second washout period of 3 days was respected, and the same broiler chickens were subjected to an identical two-way crossover (IV and PO) study with DON. The administered doses were based on the EU maximum guidance level of 5 mg DON/ kg poultry feed (European Commission 2006) . Given an average feed consumption of 4-week-old broiler chickens of 100 g feed/kg bw/day, 500 µg DON/kg bw was administered. For DON3G, an equimolar dose of 774 µg/kg bw was administered. The calculated volume of stock solution (10 mg/mL in EtOH) was diluted with saline (0.9 % NaCl) (VWR, Leuven, Belgium) up to a volume of 0.5 mL (IV) or 1 mL (PO). Feed was deprived 12 h before administration and until 3 h post-administration (p.a.). After oral administration of the toxins, 1 mL of tap water was administered to flush the gavage syringe and tube. Blood (0.5-1 mL) was sampled from the leg vein (vena metatarsalis plantaris superficialis) by venipuncture at 0 min (before administration) and at 5, 10, 20, 30, 45, 60, 90, 120 and 180 min p.a. Blood samples were centrifuged (2851×g, 10 min, 4 °C) and plasma was stored at ≤−15 °C until analysis.
Pigs
For the pig study, six clinically healthy male pigs (11 weeks of age, 26.3 ± 1.8 kg bw) were individually housed and were provided feed and water ad libitum. Natural lighting was applied, the enclosure was climate-controlled to keep the temperature between 20 and 24 °C and the relative humidity between 20 and 40 %. After a 1-week acclimatisation period, double lumen catheters were surgically placed into the vena jugularis of all six pigs. Additionally, in four of the six pigs a single lumen catheter was placed into the vena porta to study presystemic hydrolysis and biotransformation. The surgical procedure was as previously described ). After a period of 2 days, the animals were treated with DON3G by IV bolus injection using one lumen of the double lumen jugular catheters, or PO by means of gavage in the stomach, in a two-way crossover design. After DON3G administration, an identical crossover administration with DON was set up in the same animals and respecting a washout period of 24 h between treatments. Twelve h before administration of the mycotoxins, the animals were fasted until 4 h p.a. The administered doses were calculated as for the broiler chicken trial. The EU maximum guidance level in pig feed is 0.9 mg/kg DON (European Commission 2006) . Pigs at 12 weeks of age consume on average 40 g feed/kg bw/day. This resulted in the administration of 36 µg DON/kg bw. For DON3G, an equimolar dose of 55.7 µg/kg bw was administered. The calculated amount of toxin for each animal, dissolved in EtOH at 10 mg/mL, was diluted with saline to a volume of 1 (IV) or 10 mL (PO). After oral administration of the toxins, 50 mL of tap water was administered to flush the gavage syringe and tube. Blood (1-2 mL) was sampled via the other lumen of the jugular catheter and the vena porta catheter at 0 min (before administration) and at 5, 10, 20, 30, 45, 60, 90, 120, 240, 360 and 480 min p.a. Blood samples were centrifuged (2851×g, 10 min, 4 °C) and plasma was stored at ≤−15 °C until analysis.
The chicken and pig animal trials were approved by the Ethics Committee of the Faculty of Veterinary Medicine and Bioscience Engineering of Ghent University (EC2013/64 and EC2015/14, respectively).
Plasma sample preparation
Blank plasma was obtained by the collection of heparintreated blood from six different broiler chickens and pigs. The animals were fasted 12 h prior to blood collection. Plasma was obtained by centrifugation (2851×g, 10 min, 4 °C) of the blood. The blank plasma was pooled, homogenised and stored at ≤−15 °C until use for the preparation of matrix-matched calibrators and quality control samples.
Calibrator and quality control samples
To 250 µL of blank plasma, 25 µL of a 100 ng/mL IS working solution ( 13 C 15 -DON) and appropriate volumes of the standard mixture working solutions (1, 10 100 and 1000 ng/mL) were added to obtain calibrator samples with mycotoxin concentrations of 0.1, 0.5, 1, 5, 10, 50, 100 and 500 ng/mL. After vortexing, acetonitrile was added up to a volume of 1 mL to precipitate plasma proteins. The samples were vortexed again, followed by a centrifugation step (10 min at 8517×g, 4 °C). The supernatant was transferred to a new tube and evaporated to dryness under nitrogen at 45 °C. The dry residue was then redissolved in 200 µL of UHPLC-MS grade water and micro-filtrated, and 10 µL was injected onto the LC-MS/MS instrument.
Incurred samples
To 250 µL of plasma, 25 µL of a 100 ng/mL IS working solution was added. After vortexing, the samples were subjected to the same sample preparation procedure as the calibrator samples.
Blank samples
After the addition of 750 µL of acetonitrile to 250 µL of blank plasma, the samples were extracted in the same way as the calibrator samples.
LC-MS/MS analysis and validation
Separation of DON, 13 C 15 -DON, DON3G and DOM-1 was achieved on a Hypersil Gold (reversed-phase) (50 × 2.1 mm i.d., 1.9 μm) column with a guard column (10 × 2.1 mm i.d., 5 μm) of the same type. Chicken and pig plasma were analysed on an Acquity UPLC ® system coupled to a Xevo Table 1 . Instrumental and compound-specific parameters were optimised by the direct infusion of 10 ng/mL standard solutions in methanol/water (50/50, v/v) + 0.3 % glacial acetic acid with a flow rate of 10 µL/min. For the Xevo TQ-S, the desolvation gas flow rate was fixed to 800 L/h with a temperature of 550 °C, the cone gas flow rate was set at 150 L/h, capillary voltage was optimised at 3.0 kV and a collision gas flow of 0.15 mL/min was used. Dwell times of 44-52 ms/ transition were chosen. Compound-specific MS parameters, together with precursor and product ions used for quantification and qualification, are given in Table 1 Linearity of the response of the compounds was assessed by means of three matrix-matched calibration curves consisting of eight calibration points in the range of 0.1-500 ng/mL. The correlation coefficients (r) and goodness-of-fit coefficients (gof) were determined, and limits were set at ≥0.99 and ≤20 %, respectively.
Within-day accuracy & precision were determined by analysing six samples fortified at a low concentration level (limit of quantitation (LOQ) of the compounds) and at a high concentration level (100 ng/mL). Values for the relative standard deviation (RSD) could not exceed 2/3 of the RSD max , calculated according to the Horwitz equation, i.e. RSD max = 2
(1−0.5logConc) × 2/3. The acceptance criteria for accuracy were as follows: −30 to +10 % and −20 to +10 % for concentrations between 1 and 10 ng/mL, and ≥10 ng/mL, respectively. Between-day accuracy and precision were assessed by analysing the low and high concentration levels in threefold on three consecutive days (n = 3 × 3). The acceptance criteria for accuracy were identical to the values given above and RSD values could not exceed RSD max = 2
(1−0.5logConc) .
The LOQ was calculated as the lowest concentration for which the method had acceptable results with regard to accuracy and precision. It was determined by spiking six blank plasma samples. The LOQ was also established as the lowest point of the calibration curve. The limit of detection (LOD) was calculated using the samples spiked at the LOQ level (n = 6) corresponding to the concentration that could be determined with a signal-to-noise (S/N) ratio of 3.
Carry-over was evaluated by analysing a mixture of mobile phase A and B (50/50; v/v) directly after the highest calibrator (500 ng/mL).
The specificity, the capability of the method to distinguish signals of the analytes from any other substances or interferences, was determined on six blank plasma samples. For an acceptable specificity, the S/N ratio of possible interfering peaks with similar retention times in these samples could not exceed the S/N ratio of 3.
Recovery and matrix effects. Two types of matrix-matched calibration curves were prepared by spiking blank calibrator samples before and after extraction. A third calibration curve was prepared in standard solution. All curves consisted of eight calibration points in the range of 0.1-500 ng/mL. The slopes of these calibration curves (external calibration, without IS) were compared to calculate the apparent recovery (R A = 100 × slope spiked before extraction/slope standard solution), the matrix effect denoted as signal suppression/ enhancement (SSE = 100 × slope spiked after extraction/ slope standard solution) and the recovery of the extraction step (R E = 100 × slope spiked before extraction/slope spiked after extraction). Regarding SSE, values ≤1 indicate ion suppression due to matrix effect and values ≥1 indicate ion enhancement (Matuszewski et al. 2003) .
High-resolution mass spectrometry
To determine the presence of phase II metabolites, i.e. glucuronide and sulphate conjugates, high-resolution mass spectrometry (HRMS) analysis was performed on pig and broiler chicken plasma samples from three animals after IV and PO administration for identification and semiquantification of DON3G, DON and its metabolites. The methodology was similar as in a previously described study (Devreese et al. 2015) . Sample treatment, HPLC column and mobile phases were identical to the LC-MS/MS analysis. However, a different gradient elution program was applied: 0- 
Toxicokinetic modelling and statistical analysis
Toxicokinetic analysis on the LC-MS/MS data was performed using WinNonlin Professional version 5.2.1. (Pharsight, St-Louis, MO). Plasma concentrations below the LOQ were not taken into account. For the toxicokinetic analysis, all values were recalculated to their molar concentrations, expressed as nmol/mL. For the analysis of DON IV and PO data in chickens and pigs, and for DON3G IV and PO in chickens, a tailor-made two-compartmental model [central compartment (Vc) and peripheral compartment (Vp)] with first-order absorption and first-order elimination kinetics was applied. For the IV and PO administration of DON3G in pigs, a tailor-made onecompartmental model was fitted. Due to a lag time after PO DON3G administration to pigs, only terminal concentration points were above the LOQ. Consequently, it was not possible to calculate toxicokinetic parameters for the individual animals, and these parameters have been calculated simultaneously on all pooled pig PO DON3G data. As a result, no standard deviations could be calculated, and instead, coefficients of variation of the models' predicted versus observed concentrations are provided.
In Figs. 1 and 2 , a graphical representation of the constructed model is given for DON (IV & PO) and DON3G (IV & PO) in broiler chickens and pigs, respectively.
A 1/ŷ weighing was applied for all calculations with both the chicken and pig data. For all the described models, the Gauss-Newton (Levenberg and Hartley) algorithm was used with a maximum of 50 iterations.
The following primary and secondary toxicokinetic parameters were calculated for DON and DON3G after IV and PO administration: absorption rate constant (ka), intercompartmental flow (Q), total body clearance (CL), central volume of distribution (Vc), peripheral volume of distribution (Vp). FRAC is the absorbed fraction of the dose in either form (DON or DON3G). F indicates the absolute oral bioavailability, i.e. the fraction of DON or DON3G absorbed in the systemic circulation in its unchanged form. When both a central and peripheral volume of distribution were observed, the disposition rate constant (β) was calculated by dividing the Cl by the sum of Vc and Vp for each animal. When only a central volume of distribution was used, the elimination rate constant (ke) was calculated by dividing the Cl by the Vc for each animal. Presystemic hydrolysis (Pres. Hydr.) was the percentage of the total dose of DON3G that is hydrolysed presystemically to DON and absorbed as DON (%). Additionally, for PO data the descriptive toxicokinetic parameters maximal plasma concentration (C max ) and time to C max (t max ) were given for DON. Elimination half-lives (t 1/2el ) were calculated as 0.693/β or 0.693/ke.
Statistical analysis of FRAC, F, C max and t max after DON3G administration compared with DON administration consisted of one-way ANOVA with post hoc Scheffé tests (p value <0.05) for both animal species (SPSS 20.0, IBM, Chicago, IL). Equality of variances criterion was determined by the Levene's test for homogeneity of variances (p value >0.01).
Results and discussion
LC-MS/MS method validation
For the calibration model a linear, 1/x weighed, fitting was applied. The results for linearity (r and gof) and sensitivity (LOD and LOQ) are given in Table 2 . The results for linearity were all in accordance with the acceptance criteria, with r ≥ 0.99 and gof ≤ 20 %. For chicken plasma, the LOD varied from 0.11 (DOM-1) to 0.47 (DON) ng/ mL, whereas the LOQ was 1 ng/mL for all compounds. For pig plasma, LOD values ranged from 0.01 (DON) to 0.28 (DOM-1) ng/mL and LOQ values were 0.1 (DON3G), 0.5 (DON) and 1 (DOM-1) ng/mL.
The results for matrix effects (SSE), apparent recovery (R A ) and extraction recovery (R E ) are also depicted in Table 2 . SSE values for all mycotoxins varied from 44 to 112 %, which demonstrated the need for matrix-matched calibration curves for a correct quantification. The matrix effects could be diminished by further optimising the sample cleanup. However, a more elaborate cleanup tends to diminish the R E , possibly limiting the sensitivity of the method. Values for R E varied between 68.2 and 97.0 % and R A values ranged from 41.8 to 76.2 %, with the majority of the latter deviation caused by SSE. Table 3 displays the results for accuracy (%) and precision (RSD, %). All results for chicken as well as pig plasma were within the acceptable ranges. The specificity test demonstrated that no interfering peaks were detected in the chromatographic elution zone of the analytes with S/N values ≥3 (results not shown).
Carryover was evaluated and for none of the compounds signals were detected that could interfere with the response/ area of the analytes at their given retention time (results not shown).
Toxicokinetic analysis
The goal of this study was to determine the absolute oral bioavailability of DON3G and DON, the degree of in vivo figure online) hydrolysis of DON3G to DON (differentiating between presystemic GI, presystemic portal, presystemic hepatic and systemic hydrolyses) and the toxicokinetic parameters of both toxins in broiler chickens and pigs. A tailor-made compartmental toxicokinetic model was developed which offers the advantage, compared with non-compartmental analysis, that for a given compound, and PO and IV data can be fitted simultaneously for each animal allowing more reliable estimates as more data are available (Broekaert et al. 2015b ). For broiler chickens, no adverse effects were observed during the animal trial following PO and IV bolus administration of the mycotoxins. Similarly, no adverse effects were observed during the pig trial following IV and PO DON3G administration and PO DON administration. Following IV dosing of DON, two out of six pigs vomited within 0.5 h p.a. However, this had no observable influence on the results as these pigs were IV dosed.
Plasma concentration-time profiles for DON3G and DON in broiler chickens and pigs are presented in Fig. 3 . Each profile represents the mean of six animals ± SD for systemic plasma concentrations. Additionally for pigs, vena porta plasma concentration-time profiles are presented as mean of four animals ± SD. A first observation is the absence of DOM-1 in all analysed samples. The derived toxicokinetic results are shown in Table 4 .
The FRAC of PO administered DON and DON3G to chickens and PO administered DON to pigs was calculated using the tailor-made model. However, the FRAC of DON3G to pigs could not be calculated by this model as after PO administration of DON3G only DON was recovered and after IV administration only DON3G. The FRAC was therefore calculated manually by correcting the area under the curve (AUC) of DON3G after IV administration by multiplying this value with its Cl, and by correcting the AUC of DON after PO DON3G dosing again by multiplying this value with its Cl and by correcting this ratio for the difference in molar masses, as shown in the formula below:
The mean (±SD) absorbed fractions of DON and DON3G in broiler chickens were 5.56 ± 2.05 and 3.79 ± 2.68 %, respectively. Moreover, for DON and DON3G in chickens, F was equal to FRAC as DON and DON3G are absorbed in their unchanged form. The FRAC of DON in pigs, 81.3 ± 17.4 %, was also identical to the F. The FRAC of DON3G in pigs was 16.1 ± 5.4 %. However, as after PO DON3G administration only DON was recovered, F equals 0, indicating complete hydrolysis of the absorbed fraction. The higher observed FRAC values for Table 2 Validation results for linearity (r & gof, 8 concentration points in the range LOQ-500 ng/mL), sensitivity (LOD & LOQ; n = 6), matrix effects (SSE), apparent recovery (R A ) and extraction recovery (R E )
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LOQ 500 ng/mL LOQ 500 ng/mL LOQ 500 ng/mL LOQ 500 ng/mL pigs compared with chickens is an important contributing factor to the decreased sensitivity of the latter species and may be partially caused by its rapid GI transit time, leading to a reduced time for absorption in chickens. After IV administration of DON3G to chickens and pigs, no hydrolysis to DON could be observed, indicating the absence of systemic hydrolysis for both species. For pigs, this confirms the findings of Nagl et al. (2014) . After PO administration of DON3G to chickens, hydrolysis was not observed either. In contrast, after PO DON3G administration to pigs, only DON was recovered, indicating a complete presystemic hydrolysis of the absorbed fraction. Presystemic hydrolysis can take place at the level of GI microbiota, GI tissues, portal blood or the liver. To further determine the site of presystemic hydrolysis, blood was collected from the porcine vena porta, which drains the venous intestinal blood to the liver first. Interestingly, only DON was recovered and no DON3G was detected in these portal plasma samples after PO DON3G administration. This absence of DON3G in portal plasma as well as the absence of DON after IV DON3G administration indicates that hydrolysis occurs at the site of the GI tract (microbiota or GI tissues) and not in portal blood nor in the liver. This is in accordance with previously reported in vitro results which reported that hydrolysis could be caused by intestinal microbiota and which have demonstrated the important role of microbiota composition and the abundance in the intestinal tract (Abbott 2004; Berthiller et al. 2011; Dall'Erta et al. 2013; Gratz et al. 2013; Hattori and Taylor 2009 ). Furthermore, β-glucosidase from humans and almonds proved incapable of DON3G hydrolysis to DON, a typical trait of microorganisms (Berthiller et al. 2011) . The observed lag time for DON absorption after PO administration of DON3G to pigs, 83.6 min, further supports the hypothesised intestinal hydrolysis of DON3G. This is also reflected in the significant higher t max value of DON after PO DON3G administration in pigs. DON is mainly absorbed in the proximal part of the small intestine by means of passive diffusion. A less effective passive nonionic diffusion is expected for DON3G as it is more polar Fig. 3 Systemic plasma (chickens and pigs) and vena porta plasma (pigs) concentration-time profiles of deoxynivalenol (DON) and deoxynivalenol-3-β-d-glucoside (DON3G) after oral (PO) and intravenous (IV) administration (post-administration = p.a.) of DON (dose = 500 µg DON/kg body weight) and DON3G (dose = 774 µg DON3G/kg body weight) to broiler chickens and of DON (dose = 36 µg DON/kg body weight) and DON3G (dose = 55.7 µg DON3G/kg body weight) to pigs (n = 6 for systemic plasma, n = 4 for plasma from vena porta). Values are presented as mean + SD. No DON was detected in chickens after DON3G administration. In pigs, no DON was detected after IV DON3G administration and no DON3G after PO DON3G administration. The inserts show PO administration data in more detail and has a less favourable log D value (−2.74) compared with DON (−0.97) at both physiological and acidic pH values (Maresca 2013) . The pH in the stomach and duodenum of adult pigs is 4.4 and 6.4-7.4, respectively (Merchant et al. 2011 ). These rather low pH values are unfavourable for most GI commensal bacteria. When moving to more distal parts of the small intestine, the pH increases and a more abundant growth of microbiota is observed (Maresca 2013) . Consequently, the probability of DON3G hydrolysis to DON is increased, resulting in the observed lag time of 83.6 min. As chickens have a high bacterial load at the crop; thus, before the small intestine, which is the main site of absorption, hydrolysis of DON3G to DON by GI microbiota would be expected after PO administration to chickens. For pigs, where the high bacterial load is located after the site of absorption, only limited hydrolysis to DON is expected. Remarkably, our observations were the opposite of these theoretical expectations. This discrepancy likely finds its cause in the bacterial species composition and abundance in both the chicken crop and pig distal small and large intestine.
The microbiota of pigs and chickens consist mainly of the phyla Firmicutes and Bacteroidetes, accounting for approximately 90 and 80 % of the relative abundance, respectively (Kim and Isaacson 2015; Waite and Taylor 2015) . The crop, anterior small intestine, duodenal and jejunal epithelial cells, and digesta of chicken are dominated by Lactobacillus spp. (Watkins and Kratzer 1983) . Table 4 Toxicokinetic parameters, presystemic hydrolysis of the bioavailable fraction (%) and absolute oral bioavailability (F %) of DON and DON3G after IV and PO administration to broiler chickens and pigs (n = 6) Values are presented as mean ± SD. For pigs, the DON3G PO parameters have been calculated simultaneously on all pooled pig PO DON3G data; as a result, no SD could be calculated, instead coefficients of variation of the models' predicted versus the observed concentrations are given ka DON absorption rate constant for DON (1/min), ke DON elimination rate constant for DON (1/min), β DON disposition rate constant for DON (1/ min), t 1/2elDON elimination half-life of DON (min), Cl DON clearance of DON (mL/min/kg), Q DON intercompartmental flow for DON (mL/min/ kg), Vc DON central volume of distribution for DON (mL/kg), Vp DON peripheral volume of distribution for DON (mL/kg), t lag absorption lag time (min), ka DON3G absorption rate constant of DON3G (1/min), ke DON3G elimination rate constant for DON3G (1/min), β DON3G disposition rate constant for DON3G (1/min), t 1/2elDON3G elimination half-life of DON3G (min), Cl DON3G clearance of DON3G (mL/min/kg), Q DON3G intercompartmental flow for DON3G (mL/min/kg), Vc DON3G central volume of distribution for DON3G (mL/kg), Vp DON3G peripheral volume of distribution for DON3G (mL/kg), FRAC absorbed fraction, Pres.Hydr. percentage of the total dose that is hydrolysed presystemically to DON and absorbed as DON (%), F absolute oral bioavailability (%), C max maximum plasma concentration for DON (ng/mL), t max time to maximum plasma concentration for DON (min) * and ** statistically significant difference at p < 0.05 and p < 0.01, respectively, compared with DON values in the same animal species The hydrolytic capacity of Lactobacillus spp. towards DON3G has been described (Berthiller et al. 2011 (Berthiller et al. 2011) . The occurrence of both Enterococcus species has been described in the GI tract of both chickens and pigs. Possibly, the relative amounts of Enterococcus and Lactobacillus species in the GI microbiota could partially explain our in vivo findings. However, the GI microbiota of animals consists of a multitude of phyla and genus, demonstrating interspecies as well as intraspecies differences, and differing between intestinal sections, providing a multitude of options for the observed differences in hydrolysis between chickens and pigs. The mean (±SD) ka DON values in chickens and pigs were comparable, 0.0315 ± 0.0173/min and 0.0274 ± 0.0107/min, respectively. For pigs ka DON values of 0.00995 ± 0.00292/min (Eriksen et al. 2003) , 0.0310 ± 0.0238/min (Goyarts and Dänicke 2006) and 0.0164 ± 0.0161/min (Broekaert et al. 2015b ) have been reported, and for chickens, a ka DON of 0.0203 ± 0.0101/ min (Broekaert et al. 2015b ) was previously described. The ka DON3G in chickens was slightly lower than that of DON, 0.0238 ± 0.0203/min. For pigs, no ka DON3G could be calculated as it was fully hydrolysed to DON after PO administration. The resulting ka DON after PO DON3G administration was 0.00501/min, significantly lower than the ka DON after DON administration. The ka DON after PO DON3G administration is influenced by presystemic hydrolysis; consequently, this value is also determined by biotransformation in addition to absorption.
With regard to clearance, mean (±SD) Cl DON3G values of 11.4 ± 1.2 and 3.17 ± 0.81 mL/min/kg were obtained for chickens and pigs, respectively. Cl DON values in chickens and pigs were 88.8 ± 12.4 and 5.25 ± 1.25 mL/min/kg, DON/kg body weight) and DON3G (dose = 55.7 µg DON3G/kg body weight) to pigs (n = 3 for systemic plasma, n = 3 for plasma from vena porta). Values are presented as mean + SD respectively. For chickens, a comparable Cl DON of 120 mL/ min/kg (Osselaere et al. 2013 ) and 102 ± 12 mL/min/kg (Broekaert et al. 2015b ) have previously been described. Cl DON values in pigs of 9.30 ± 3.95 mL/min/kg (acute PO) (Goyarts and Dänicke 2006) , 5.30 ± 1.64 mL/min/kg (chronic PO) (Goyarts and Dänicke 2006) , 15.1 ± 3.8 mL/ min/kg (acute PO) (Broekaert et al. 2015b ) and a Cl DON /F of 5.0 ± 0.7 mL/min/kg (acute PO) (Devreese et al. 2014) have been reported, which are in the same range as the results in this study. The obtained mean (±SD) Vc DON and Vp DON values for chickens were 1350 ± 578 and 1087 ± 211 mL/kg, respectively. For pigs, Vc DON and Vp DON values were comparable, i.e. 614 ± 127 and 789 ± 486 mL/kg, respectively. For chickens, Vc DON3G and Vp DON3G values of 290 ± 188 and 284 ± 167 mL/kg were obtained. A Vd DON3G in pigs of 249 ± 67 mL/kg was obtained using a one-compartmental model. The observed lower Vd values for DON3G indicate that DON3G is more confined to intravascular fluids than DON, which can be theoretically explained by its increased polarity compared with DON, resulting in less effective passive non-ionic diffusion into tissues.
The mean (±SD) elimination half-lives (t 1/2el ) for DON in broilers and pigs were 18.8 ± 2.1 and 163 ± 59 min (2.71 h), respectively. For pigs, t 1/2el of 5.3 ± 2.4 h (acute PO, two-compartmental model) (Goyarts and Dänicke 2006) , 2.4 ± 0.7 h (acute PO, one-compartmental model) (Eriksen et al. 2003) , 2.7 ± 0.5 h (acute PO, one-compartmental model) (Devreese et al. 2014 ) and 2.9 h (acute PO, two-compartmental model) (Broekaert et al. 2015b) were observed. For broiler chickens, comparable elimination half-lives of 27.9 ± 6.9 (IV) and 38.2 ± 11.2 min (acute PO) (Osselaere et al. 2013 ) and 17.9 min (acute PO) (Broekaert et al. 2015b ) were also reported. The t 1/2elDON3G values for chickens and pigs were 34.0 ± 6.2 and 54.1 ± 3.0 min, respectively. Remarkably, the t 1/2elDON3G compared with that of DON was increased for chickens and decreased for pigs, highlighting the difference between both species with respect to DON3G's elimination. For pigs, this is mainly attributed to a lower Vd. For broiler chickens, additional to a lower Vd a reduced Cl was observed.
HRMS
The plasma concentration-time profiles of phase II metabolites are depicted in Figs. 4 and 5 for pigs and chickens, respectively. Since only semi-quantitative analysis was performed, absolute peak areas obtained on the HRMS instrument are depicted. For pigs, a first observation is that glucuronidation patterns after PO administration do not differ between systemic (vena jugularis) and presystemic (vena porta) plasma. This indicates that glucuronidation does not occur presystemically to a significant rate and extent. This hypothesis is further supported by practically identical observed mean glucuronidation ratios (area of DONGlcA/area of DON) after IV and PO administration, 4.94 and 4.98, respectively. For pigs, no sulphate conjugates were detected, in agreement with the previously reported lack of sulphation reactions in this species (Riviere and Papich 2013) . In contrast, chickens predominantly formed DON-3sulphate. The mean DON-3-sulphate/DON ratios in chickens after IV and PO DON administration were 392 and 9890, respectively. The observed ratios are comparable to previously found values for IV and PO administration of DON to chickens of 243-453 and 1365-29,624, respectively (Devreese et al. 2015) . This remarkable contrast in ratio between IV and PO administration points towards a presystemic sulphation of DON, either by GI microbiota, GI tissues or a presystemic liver effect. In chickens, no glucuronidation was observed. The extensive and rapid sulphation in chickens might partially explain the relative resistance of this species towards the detrimental effects of DON.
In conclusion, broiler chickens do not hydrolyse DON3G to DON in vivo. Additionally, DON3G has a low absolute oral bioavailability (3.79 ± 2.68 %) comparable to that of DON (5.56 ± 2.05 %). After PO DON3G administration to pigs, only DON was recovered, indicating a complete presystemic hydrolysis of DON3G. However, the absorbed fraction is approximately 5 times lower than after PO DON administration, 16.1 ± 5.4 compared with 81.3 ± 17.4 %. Analysis of phase II metabolites revealed that DON biotransformation in pigs consists mainly of glucuronidation, and in chickens predominantly sulphation occurs, which is absent in pigs. Phase II biotransformation is much more extensive for chickens than for pigs, which is a possible explanation for the differences in sensitivity of the latter species to DON. Furthermore, given the in vivo hydrolysis of DON3G in pigs, pigs are likely to be more sensitive to this modified mycotoxin compared with chickens. Although in vitro studies reported that DON3G is less toxic than DON, the demonstrated in vivo hydrolysis to DON in pigs, as well as the interspecies differences observed, indicates a decreased yet not neglectable toxicological relevance of DON3G and consequently warrants further research to establish a tolerable daily intake.
